<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756418</url>
  </required_header>
  <id_info>
    <org_study_id>0476-396</org_study_id>
    <secondary_id>MK0476-396</secondary_id>
    <secondary_id>2008_027</secondary_id>
    <nct_id>NCT00756418</nct_id>
  </id_info>
  <brief_title>Montelukast Post-marketing Comparative Study With Theophyline Added to Inhaled Corticosteroid (0476-396)</brief_title>
  <official_title>A Randomized Open-Label Comparative Study of Montelukast Versus Theophylline Added to Inhaled Corticosteroid in Pediatric Patients With Bronchial Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      A clinical study explores the safety and efficacy of montelukast and to compare the safety
      and efficacy of montelukast with those of theophylline in pediatric bronchial asthma patients
      when they are used in conjunction with inhaled steroids.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2003</start_date>
  <completion_date type="Actual">August 28, 2004</completion_date>
  <primary_completion_date type="Actual">August 28, 2004</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of AM PEF over first 2 Weeks</measure>
    <time_frame>Over first 2 Weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>montelukast</intervention_name>
    <description>montelukast 5 mg QD 4-weeks.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK0476</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline</intervention_name>
    <description>Theophylline 100 to 200 mg BID 4-weeks.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric Bronchial Asthma Patients Aged 6 To 14 Years (At The Beginning Of The
             Treatment Period)

          -  The Severity Must Be Mild, Moderate Or Severe, Persistent Bronchial Asthma

          -  The Patient Must Have Symptoms That Can Be Used As Efficacy Variables (Such As
             Repeated Coughing And Mild Or Moderate Asthma Attacks) During The Observation Period,
             And Must Be Using Inhaled Steroids

        Exclusion Criteria:

          -  Patient Using Anti-Asthma Treatment Or Therapy Including corticosteroids Or Oral
             Anti-Allergic Drugs

          -  Patient With Complications That Will Impair The Judgment Of Efficacy Of This Drug

          -  Patient With Convulsive Disorders Such As Epilepsy Or Such A History

          -  Patient With Liver Disease, Renal Impairment, Heart Disease Or Such Other Complication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <results_reference>
    <citation>Kondo N, Katsunuma T, Odajima Y, Morikawa A. A randomized open-label comparative study of montelukast versus theophylline added to inhaled corticosteroid in asthmatic children. Allergol Int. 2006 Sep;55(3):287-93.</citation>
    <PMID>17075269</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2008</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <study_docs>
    <study_doc>
      <doc_type>CSR Synopsis</doc_type>
      <doc_url>http://www.merck.com/clinical-trials/policies-perspectives.html</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

